These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9052337)

  • 1. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial).
    Bovill EG; Tracy RP; Knatterud GL; Stone PH; Nasmith J; Gore JM; Thompson BW; Tofler GH; Kleiman NS; Cannon C; Braunwald E
    Am J Cardiol; 1997 Feb; 79(4):391-6. PubMed ID: 9052337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
    Bovill EG; Terrin ML; Stump DC; Berke AD; Frederick M; Collen D; Feit F; Gore JM; Hillis LD; Lambrew CT
    Ann Intern Med; 1991 Aug; 115(4):256-65. PubMed ID: 1906692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
    Anderson HV; Cannon CP; Stone PH; Williams DO; McCabe CH; Knatterud GL; Thompson B; Willerson JT; Braunwald E
    J Am Coll Cardiol; 1995 Dec; 26(7):1643-50. PubMed ID: 7594098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.
    Circulation; 1994 Apr; 89(4):1545-56. PubMed ID: 8149520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
    Becker RC; Cannon CP; Tracy RP; Thompson B; Bovill EG; Desvigne-Nickens P; Randall AM; Knatternud G; Braunwald E
    Am Heart J; 1996 Mar; 131(3):421-33. PubMed ID: 8604620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.
    Williams DO; Topol EJ; Califf RM; Roberts R; Mancini GB; Joelson JM; Ellis SG; Kleiman NS
    Circulation; 1990 Aug; 82(2):376-83. PubMed ID: 2115407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
    TIMI Study Group
    N Engl J Med; 1989 Mar; 320(10):618-27. PubMed ID: 2563896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo.
    Freeman MR; Langer A; Wilson RF; Morgan CD; Armstrong PW
    Circulation; 1992 Jan; 85(1):150-7. PubMed ID: 1728444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary revascularization after intravenous tissue plasminogen activator for unstable angina pectoris: results of a randomized, double-blind, placebo-controlled trial.
    Topol EJ; Nicklas JM; Kander NH; Walton JA; Ellis SG; Gorman L; Pitt B
    Am J Cardiol; 1988 Sep; 62(7):368-71. PubMed ID: 2970776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
    Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
    N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris.
    Ardissino D; Barberis P; De Servi S; Mussini A; Rolla A; Visani L; Specchia G
    Am J Cardiol; 1990 Oct; 66(12):910-4. PubMed ID: 2121016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators.
    O'Connor CM; Meese RB; McNulty S; Lucas KD; Carney RJ; LeBoeuf RM; Maddox W; Bethea CF; Shadoff N; Trahey TF; Heinsimer JA; Burks JM; O'Donnell G; Krucoff MW; Califf RM
    Am J Cardiol; 1996 Apr; 77(10):791-7. PubMed ID: 8623729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patency trials with reteplase (r-PA): what do they tell us?
    Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
    Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
    Gurfinkel EP; Manos EJ; Mejaíl RI; Cerdá MA; Duronto EA; García CN; Daroca AM; Mautner B
    J Am Coll Cardiol; 1995 Aug; 26(2):313-8. PubMed ID: 7608429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina.
    Nicklas JM; Topol EJ; Kander N; O'Neill WW; Walton JA; Ellis SG; Gorman L; Pitt B
    J Am Coll Cardiol; 1989 Feb; 13(2):434-41. PubMed ID: 2492325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.
    Circulation; 1993 Jan; 87(1):38-52. PubMed ID: 8419023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
    N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.
    Gold HK; Johns JA; Leinbach RC; Yasuda T; Grossbard E; Zusman R; Collen D
    Circulation; 1987 Jun; 75(6):1192-9. PubMed ID: 3105913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
    Cannon CP; Weintraub WS; Demopoulos LA; Robertson DH; Gormley GJ; Braunwald E
    Am J Cardiol; 1998 Sep; 82(6):731-6. PubMed ID: 9761082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.